Fibrillazione atriale (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fibrillazione atriale" in Italian language version.

refsWebsite

Global rank Italian rank

4^th place

9^th place

2^nd place

7^th place

799^th place

22^nd place

2web.archive.org

1^st place

1^st place

6^th place

8^th place

1onlinejacc.org

low place

low place

1heartlungcirc.org

low place

low place

1oxfordjournals.org

1,389^th place

732^nd place

low place

low place

1escardio.org%7CThe

low place

low place

aiac.it

A.Raviele, Linee guida AIAC per la gestione e il trattamento della fibrillazione atriale. Aggiornamento 2013 (PDF), su aiac.it. URL consultato il 23 ottobre 2015.

archive.org

J. Heeringa et al., Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study., in Am Heart J, vol. 156, n. 6, dicembre 2008, pp. 1163-9, DOI:10.1016/j.ahj.2008.08.003, PMID 19033014.
KT. Konings et al., High-density mapping of electrically induced atrial fibrillation in humans., in Circulation, vol. 89, n. 4, aprile 1994, pp. 1665-80, PMID 8149534.

doi.org

dx.doi.org

Roy D et al., Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure, in N Engl J Med, n. 358, 2008, pp. 2667–2677, DOI:10.1056/NEJMoa0708789, PMID 18565859.
Wyse DG et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation, in N Engl J Med, n. 347, 2002, pp. 1825–1833, DOI:10.1056/NEJMoa021328, PMID 12466506.
Carlsson J et al., Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study, in J Am Coll Cardiol, n. 41, 2003, pp. pagg.1690-1696, DOI:10.1016/S0735-1097(03)00332-2, PMID 12767648.
Hohnloser SH, Kuck KH e Lilienthal J, Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial, in Lancet, n. 356, 2000, pp. 1789–1794, DOI:10.1016/S0140-6736(00)03230-X, PMID 11117910.
Kirchhof P et al., Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), in Eur Heart J, n. 28, 2007, pp. 2803-2817, DOI:10.1093/eurheartj/ehm358, PMID 17897924.
Stewart S et al., Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, in Heart, n. 86, 2001, pp. 516–521, DOI:10.1136/heart.86.5.516, PMID 11602543.
Lloyd-Jones DM et al., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, in Circulation, n. 110, 2004, pp. 1042–1046, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Heeringa J et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, in Eur Heart J, n. 27, 2006, pp. 949–953, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Benjamin EJ et al., Independent risk factors for atrial ﬁbrillation in a population-based cohort: the Framingham Heart Study, in JAMA, vol. 271, 1994, pp. 840–4, DOI:10.1001/jama.1994.03510350050036, PMID 8114238.
Nieuwlaat R et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, in Eur Heart J, vol. 26, 2005, pp. 2422–2434, DOI:10.1093/eurheartj/ehi505, PMID 16204266.
Gersh BJ et al., 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of CardiologyFoundation/AmericanHeartAssociationTaskForce on Practice Guidelines, in J Am Coll Cardiol, n. 58, 2011, pp. e212–60, DOI:10.1016/j.jtcvs.2011.10.020, PMID 22093723.
Cappola AR et al., Thyroid status, cardiovascular risk, and mortality in older adults, in JAMA, n. 295, 2006, pp. 1033–41, DOI:10.1001/jama.295.9.1033, PMID 16507804.
Frost L et al., Overweight and obesity as risk factors for atrial ﬁbrillation or ﬂutter: the Danish Diet, Cancer, and Health Study, in Am J Med 2005, n. 118, pp. 489–95, DOI:10.1016/j.amjmed.2005.01.031, PMID 15866251.
AS. Gami et al., Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation., in J Am Coll Cardiol, vol. 49, n. 5, febbraio 2007, pp. 565-71, DOI:10.1016/j.jacc.2006.08.060, PMID 17276180.
S. Kodama et al., Alcohol consumption and risk of atrial fibrillation: a meta-analysis., in J Am Coll Cardiol, vol. 57, n. 4, gennaio 2011, pp. 427-36, DOI:10.1016/j.jacc.2010.08.641, PMID 21251583.
JP. Mathew et al., A multicenter risk index for atrial fibrillation after cardiac surgery., in JAMA, vol. 291, n. 14, aprile 2004, pp. 1720-9, DOI:10.1001/jama.291.14.1720, PMID 15082699.
LD. Hillis et al., 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons., in J Am Coll Cardiol, vol. 58, n. 24, dicembre 2011, pp. e123-210, DOI:10.1016/j.jacc.2011.08.009, PMID 22070836.
J. Heeringa et al., Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study., in Am Heart J, vol. 156, n. 6, dicembre 2008, pp. 1163-9, DOI:10.1016/j.ahj.2008.08.003, PMID 19033014.
A. Aizer et al., Relation of vigorous exercise to risk of atrial fibrillation., in Am J Cardiol, vol. 103, n. 11, giugno 2009, pp. 1572-7, DOI:10.1016/j.amjcard.2009.01.374, PMID 19463518.
L. Mont et al., Long-lasting sport practice and lone atrial fibrillation., in Eur Heart J, vol. 23, n. 6, marzo 2002, pp. 477-82, DOI:10.1053/euhj.2001.2802, PMID 11863350.
RJ. Aviles et al., Inflammation as a risk factor for atrial fibrillation., in Circulation, vol. 108, n. 24, dicembre 2003, pp. 3006-10, DOI:10.1161/01.CIR.0000103131.70301.4F, PMID 14623805.
KK. Patton et al., N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study., in Circulation, vol. 120, n. 18, novembre 2009, pp. 1768-74, DOI:10.1161/CIRCULATIONAHA.109.873265, PMID 19841297.
P. Kirchhof et al., Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association., in Europace, vol. 9, n. 11, novembre 2007, pp. 1006-23, DOI:10.1093/europace/eum191, PMID 17897925.
M. Haïssaguerre et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins., in N Engl J Med, vol. 339, n. 10, settembre 1998, pp. 659-66, DOI:10.1056/NEJM199809033391003, PMID 9725923.
TH. Everett, JE. Olgin, Atrial fibrosis and the mechanisms of atrial fibrillation., in Heart Rhythm, vol. 4, 3 Suppl, marzo 2007, pp. S24-7, DOI:10.1016/j.hrthm.2006.12.040, PMID 17336879.
SM. Narayan et al., Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial., in J Am Coll Cardiol, vol. 60, n. 7, agosto 2012, pp. 628-36, DOI:10.1016/j.jacc.2012.05.022, PMID 22818076.
(EN) AM. Kim et al., Role of atrial substrate and spatiotemporal organization in atrial fibrillation., in Heart Rhythm, vol. 6, 8 Suppl, agosto 2009, pp. S1-7, DOI:10.1016/j.hrthm.2009.02.010, PMID 19631905.
P. Kirchhof et al., Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'., in Eur Heart J, vol. 30, n. 24, dicembre 2009, pp. 2969-77c, DOI:10.1093/eurheartj/ehp235, PMID 19535417.
DM. Hodgson-Zingman et al., Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation., in N Engl J Med, vol. 359, n. 2, luglio 2008, pp. 158-65, DOI:10.1056/NEJMoa0706300, PMID 18614783.
DF. Gudbjartsson et al., A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke., in Nat Genet, vol. 41, n. 8, agosto 2009, pp. 876-8, DOI:10.1038/ng.417, PMID 19597491.
S. Neef, LS. Maier, Novel aspects of excitation-contraction coupling in heart failure., in Basic Res Cardiol, vol. 108, n. 4, luglio 2013, p. 360, DOI:10.1007/s00395-013-0360-2, PMID 23740218.
SM. Chaldoupi et al., The role of connexin40 in atrial fibrillation., in Cardiovasc Res, vol. 84, n. 1, ottobre 2009, pp. 15-23, DOI:10.1093/cvr/cvp203, PMID 19535379.
B. Burstein, S. Nattel, Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation., in J Am Coll Cardiol, vol. 51, n. 8, febbraio 2008, pp. 802-9, DOI:10.1016/j.jacc.2007.09.064, PMID 18294563.
D. Rahmutula et al., Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1., in Cardiovasc Res, vol. 99, n. 4, settembre 2013, pp. 769-79, DOI:10.1093/cvr/cvt074, PMID 23612580.
SN. Reilly et al., Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins., in Circulation, vol. 124, n. 10, settembre 2011, pp. 1107-17, DOI:10.1161/CIRCULATIONAHA.111.029223, PMID 21844076.
JY. Youn et al., Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase., in J Mol Cell Cardiol, vol. 62, settembre 2013, pp. 72-9, DOI:10.1016/j.yjmcc.2013.04.019, PMID 23643589.
J. Kornej et al., The emerging role of biomarkers in atrial fibrillation., in Can J Cardiol, vol. 29, n. 10, ottobre 2013, pp. 1181-93, DOI:10.1016/j.cjca.2013.04.016, PMID 23962731.
(EN) [Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)], Guidelines for the management of atrial fibrillation, in European Heart Journal, n. 31, 2010, pp. 2369-2429, DOI:10.1093/eurheartj/ehq278.
AR. Kansal, M. Sharma; C. Bradley-Kennedy; A. Clemens; BU. Monz; S. Peng; N. Roskell; SV. Sorensen, Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness., in Thromb Haemost, vol. 108, n. 4, settembre 2012, pp. 672-82, DOI:10.1160/TH12-06-0388, PMID 22898892.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials., in J Med Econ, vol. 15, n. 4, 2012, pp. 776-85, DOI:10.3111/13696998.2012.680555, PMID 22449118.
J. Steffel, E. Braunwald, Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism., in Eur Heart J, vol. 32, n. 16, agosto 2011, pp. 1968-76, 1976a, DOI:10.1093/eurheartj/ehr052, PMID 21421599.

escardio.org%7CThe

(EN) [Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)], Guidelines for the management of atrial fibrillation, in European Heart Journal, n. 31, 2010, pp. 2369-2429, DOI:10.1093/eurheartj/ehq278.

heartlungcirc.org

(EN) David Brieger et al., National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018, vol. 27, n. 10, 2018, pp. 1209-1266. URL consultato il 27 ottobre 2018.

nih.gov

ncbi.nlm.nih.gov

Roy D et al., Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure, in N Engl J Med, n. 358, 2008, pp. 2667–2677, DOI:10.1056/NEJMoa0708789, PMID 18565859.
Wyse DG et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation, in N Engl J Med, n. 347, 2002, pp. 1825–1833, DOI:10.1056/NEJMoa021328, PMID 12466506.
Carlsson J et al., Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study, in J Am Coll Cardiol, n. 41, 2003, pp. pagg.1690-1696, DOI:10.1016/S0735-1097(03)00332-2, PMID 12767648.
Hohnloser SH, Kuck KH e Lilienthal J, Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial, in Lancet, n. 356, 2000, pp. 1789–1794, DOI:10.1016/S0140-6736(00)03230-X, PMID 11117910.
Kirchhof P et al., Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), in Eur Heart J, n. 28, 2007, pp. 2803-2817, DOI:10.1093/eurheartj/ehm358, PMID 17897924.
Stewart S et al., Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, in Heart, n. 86, 2001, pp. 516–521, DOI:10.1136/heart.86.5.516, PMID 11602543.
Lloyd-Jones DM et al., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, in Circulation, n. 110, 2004, pp. 1042–1046, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Heeringa J et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, in Eur Heart J, n. 27, 2006, pp. 949–953, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Benjamin EJ et al., Independent risk factors for atrial ﬁbrillation in a population-based cohort: the Framingham Heart Study, in JAMA, vol. 271, 1994, pp. 840–4, DOI:10.1001/jama.1994.03510350050036, PMID 8114238.
Nieuwlaat R et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, in Eur Heart J, vol. 26, 2005, pp. 2422–2434, DOI:10.1093/eurheartj/ehi505, PMID 16204266.
Gersh BJ et al., 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of CardiologyFoundation/AmericanHeartAssociationTaskForce on Practice Guidelines, in J Am Coll Cardiol, n. 58, 2011, pp. e212–60, DOI:10.1016/j.jtcvs.2011.10.020, PMID 22093723.
Cappola AR et al., Thyroid status, cardiovascular risk, and mortality in older adults, in JAMA, n. 295, 2006, pp. 1033–41, DOI:10.1001/jama.295.9.1033, PMID 16507804.
Frost L et al., Overweight and obesity as risk factors for atrial ﬁbrillation or ﬂutter: the Danish Diet, Cancer, and Health Study, in Am J Med 2005, n. 118, pp. 489–95, DOI:10.1016/j.amjmed.2005.01.031, PMID 15866251.
AS. Gami et al., Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation., in J Am Coll Cardiol, vol. 49, n. 5, febbraio 2007, pp. 565-71, DOI:10.1016/j.jacc.2006.08.060, PMID 17276180.
S. Kodama et al., Alcohol consumption and risk of atrial fibrillation: a meta-analysis., in J Am Coll Cardiol, vol. 57, n. 4, gennaio 2011, pp. 427-36, DOI:10.1016/j.jacc.2010.08.641, PMID 21251583.
JP. Mathew et al., A multicenter risk index for atrial fibrillation after cardiac surgery., in JAMA, vol. 291, n. 14, aprile 2004, pp. 1720-9, DOI:10.1001/jama.291.14.1720, PMID 15082699.
LD. Hillis et al., 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons., in J Am Coll Cardiol, vol. 58, n. 24, dicembre 2011, pp. e123-210, DOI:10.1016/j.jacc.2011.08.009, PMID 22070836.
J. Heeringa et al., Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study., in Am Heart J, vol. 156, n. 6, dicembre 2008, pp. 1163-9, DOI:10.1016/j.ahj.2008.08.003, PMID 19033014.
A. Aizer et al., Relation of vigorous exercise to risk of atrial fibrillation., in Am J Cardiol, vol. 103, n. 11, giugno 2009, pp. 1572-7, DOI:10.1016/j.amjcard.2009.01.374, PMID 19463518.
L. Mont et al., Long-lasting sport practice and lone atrial fibrillation., in Eur Heart J, vol. 23, n. 6, marzo 2002, pp. 477-82, DOI:10.1053/euhj.2001.2802, PMID 11863350.
WB. Kannel et al., Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates., in Am J Cardiol, vol. 82, 8A, ottobre 1998, pp. 2N-9N, PMID 9809895.
RJ. Aviles et al., Inflammation as a risk factor for atrial fibrillation., in Circulation, vol. 108, n. 24, dicembre 2003, pp. 3006-10, DOI:10.1161/01.CIR.0000103131.70301.4F, PMID 14623805.
KK. Patton et al., N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study., in Circulation, vol. 120, n. 18, novembre 2009, pp. 1768-74, DOI:10.1161/CIRCULATIONAHA.109.873265, PMID 19841297.
A. Frustaci et al., Histological substrate of atrial biopsies in patients with lone atrial fibrillation., in Circulation, vol. 96, n. 4, agosto 1997, pp. 1180-4, PMID 9286947.
P. Kirchhof et al., Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association., in Europace, vol. 9, n. 11, novembre 2007, pp. 1006-23, DOI:10.1093/europace/eum191, PMID 17897925.
M. Haïssaguerre et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins., in N Engl J Med, vol. 339, n. 10, settembre 1998, pp. 659-66, DOI:10.1056/NEJM199809033391003, PMID 9725923.
TH. Everett, JE. Olgin, Atrial fibrosis and the mechanisms of atrial fibrillation., in Heart Rhythm, vol. 4, 3 Suppl, marzo 2007, pp. S24-7, DOI:10.1016/j.hrthm.2006.12.040, PMID 17336879.
KT. Konings et al., High-density mapping of electrically induced atrial fibrillation in humans., in Circulation, vol. 89, n. 4, aprile 1994, pp. 1665-80, PMID 8149534.
SM. Narayan et al., Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial., in J Am Coll Cardiol, vol. 60, n. 7, agosto 2012, pp. 628-36, DOI:10.1016/j.jacc.2012.05.022, PMID 22818076.
(EN) AM. Kim et al., Role of atrial substrate and spatiotemporal organization in atrial fibrillation., in Heart Rhythm, vol. 6, 8 Suppl, agosto 2009, pp. S1-7, DOI:10.1016/j.hrthm.2009.02.010, PMID 19631905.
P. Kirchhof et al., Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'., in Eur Heart J, vol. 30, n. 24, dicembre 2009, pp. 2969-77c, DOI:10.1093/eurheartj/ehp235, PMID 19535417.
DM. Hodgson-Zingman et al., Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation., in N Engl J Med, vol. 359, n. 2, luglio 2008, pp. 158-65, DOI:10.1056/NEJMoa0706300, PMID 18614783.
DF. Gudbjartsson et al., A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke., in Nat Genet, vol. 41, n. 8, agosto 2009, pp. 876-8, DOI:10.1038/ng.417, PMID 19597491.
MC. Wijffels et al., Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats., in Circulation, vol. 92, n. 7, ottobre 1995, pp. 1954-68, PMID 7671380.
CA. Morillo et al., Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation., in Circulation, vol. 91, n. 5, marzo 1995, pp. 1588-95, PMID 7867201.
S. Neef, LS. Maier, Novel aspects of excitation-contraction coupling in heart failure., in Basic Res Cardiol, vol. 108, n. 4, luglio 2013, p. 360, DOI:10.1007/s00395-013-0360-2, PMID 23740218.
SM. Chaldoupi et al., The role of connexin40 in atrial fibrillation., in Cardiovasc Res, vol. 84, n. 1, ottobre 2009, pp. 15-23, DOI:10.1093/cvr/cvp203, PMID 19535379.
B. Burstein, S. Nattel, Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation., in J Am Coll Cardiol, vol. 51, n. 8, febbraio 2008, pp. 802-9, DOI:10.1016/j.jacc.2007.09.064, PMID 18294563.
D. Rahmutula et al., Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1., in Cardiovasc Res, vol. 99, n. 4, settembre 2013, pp. 769-79, DOI:10.1093/cvr/cvt074, PMID 23612580.
SN. Reilly et al., Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins., in Circulation, vol. 124, n. 10, settembre 2011, pp. 1107-17, DOI:10.1161/CIRCULATIONAHA.111.029223, PMID 21844076.
JY. Youn et al., Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase., in J Mol Cell Cardiol, vol. 62, settembre 2013, pp. 72-9, DOI:10.1016/j.yjmcc.2013.04.019, PMID 23643589.
J. Kornej et al., The emerging role of biomarkers in atrial fibrillation., in Can J Cardiol, vol. 29, n. 10, ottobre 2013, pp. 1181-93, DOI:10.1016/j.cjca.2013.04.016, PMID 23962731.
AR. Kansal, M. Sharma; C. Bradley-Kennedy; A. Clemens; BU. Monz; S. Peng; N. Roskell; SV. Sorensen, Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness., in Thromb Haemost, vol. 108, n. 4, settembre 2012, pp. 672-82, DOI:10.1160/TH12-06-0388, PMID 22898892.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials., in J Med Econ, vol. 15, n. 4, 2012, pp. 776-85, DOI:10.3111/13696998.2012.680555, PMID 22449118.
J. Steffel, E. Braunwald, Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism., in Eur Heart J, vol. 32, n. 16, agosto 2011, pp. 1968-76, 1976a, DOI:10.1093/eurheartj/ehr052, PMID 21421599.

oadoi.org

Roy D et al., Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure, in N Engl J Med, n. 358, 2008, pp. 2667–2677, DOI:10.1056/NEJMoa0708789, PMID 18565859.
Wyse DG et al., Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation, in N Engl J Med, n. 347, 2002, pp. 1825–1833, DOI:10.1056/NEJMoa021328, PMID 12466506.
Carlsson J et al., Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study, in J Am Coll Cardiol, n. 41, 2003, pp. pagg.1690-1696, DOI:10.1016/S0735-1097(03)00332-2, PMID 12767648.
Hohnloser SH, Kuck KH e Lilienthal J, Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial, in Lancet, n. 356, 2000, pp. 1789–1794, DOI:10.1016/S0140-6736(00)03230-X, PMID 11117910.
Kirchhof P et al., Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), in Eur Heart J, n. 28, 2007, pp. 2803-2817, DOI:10.1093/eurheartj/ehm358, PMID 17897924.
Stewart S et al., Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, in Heart, n. 86, 2001, pp. 516–521, DOI:10.1136/heart.86.5.516, PMID 11602543.
Lloyd-Jones DM et al., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, in Circulation, n. 110, 2004, pp. 1042–1046, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Heeringa J et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, in Eur Heart J, n. 27, 2006, pp. 949–953, DOI:10.1161/01.CIR.0000140263.20897.42, PMID 15313941.
Benjamin EJ et al., Independent risk factors for atrial ﬁbrillation in a population-based cohort: the Framingham Heart Study, in JAMA, vol. 271, 1994, pp. 840–4, DOI:10.1001/jama.1994.03510350050036, PMID 8114238.
Nieuwlaat R et al., Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, in Eur Heart J, vol. 26, 2005, pp. 2422–2434, DOI:10.1093/eurheartj/ehi505, PMID 16204266.
Gersh BJ et al., 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of CardiologyFoundation/AmericanHeartAssociationTaskForce on Practice Guidelines, in J Am Coll Cardiol, n. 58, 2011, pp. e212–60, DOI:10.1016/j.jtcvs.2011.10.020, PMID 22093723.
Cappola AR et al., Thyroid status, cardiovascular risk, and mortality in older adults, in JAMA, n. 295, 2006, pp. 1033–41, DOI:10.1001/jama.295.9.1033, PMID 16507804.
Frost L et al., Overweight and obesity as risk factors for atrial ﬁbrillation or ﬂutter: the Danish Diet, Cancer, and Health Study, in Am J Med 2005, n. 118, pp. 489–95, DOI:10.1016/j.amjmed.2005.01.031, PMID 15866251.
AS. Gami et al., Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation., in J Am Coll Cardiol, vol. 49, n. 5, febbraio 2007, pp. 565-71, DOI:10.1016/j.jacc.2006.08.060, PMID 17276180.
S. Kodama et al., Alcohol consumption and risk of atrial fibrillation: a meta-analysis., in J Am Coll Cardiol, vol. 57, n. 4, gennaio 2011, pp. 427-36, DOI:10.1016/j.jacc.2010.08.641, PMID 21251583.
JP. Mathew et al., A multicenter risk index for atrial fibrillation after cardiac surgery., in JAMA, vol. 291, n. 14, aprile 2004, pp. 1720-9, DOI:10.1001/jama.291.14.1720, PMID 15082699.
LD. Hillis et al., 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons., in J Am Coll Cardiol, vol. 58, n. 24, dicembre 2011, pp. e123-210, DOI:10.1016/j.jacc.2011.08.009, PMID 22070836.
A. Aizer et al., Relation of vigorous exercise to risk of atrial fibrillation., in Am J Cardiol, vol. 103, n. 11, giugno 2009, pp. 1572-7, DOI:10.1016/j.amjcard.2009.01.374, PMID 19463518.
L. Mont et al., Long-lasting sport practice and lone atrial fibrillation., in Eur Heart J, vol. 23, n. 6, marzo 2002, pp. 477-82, DOI:10.1053/euhj.2001.2802, PMID 11863350.
RJ. Aviles et al., Inflammation as a risk factor for atrial fibrillation., in Circulation, vol. 108, n. 24, dicembre 2003, pp. 3006-10, DOI:10.1161/01.CIR.0000103131.70301.4F, PMID 14623805.
KK. Patton et al., N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study., in Circulation, vol. 120, n. 18, novembre 2009, pp. 1768-74, DOI:10.1161/CIRCULATIONAHA.109.873265, PMID 19841297.
P. Kirchhof et al., Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association., in Europace, vol. 9, n. 11, novembre 2007, pp. 1006-23, DOI:10.1093/europace/eum191, PMID 17897925.
M. Haïssaguerre et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins., in N Engl J Med, vol. 339, n. 10, settembre 1998, pp. 659-66, DOI:10.1056/NEJM199809033391003, PMID 9725923.
TH. Everett, JE. Olgin, Atrial fibrosis and the mechanisms of atrial fibrillation., in Heart Rhythm, vol. 4, 3 Suppl, marzo 2007, pp. S24-7, DOI:10.1016/j.hrthm.2006.12.040, PMID 17336879.
SM. Narayan et al., Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial., in J Am Coll Cardiol, vol. 60, n. 7, agosto 2012, pp. 628-36, DOI:10.1016/j.jacc.2012.05.022, PMID 22818076.
(EN) AM. Kim et al., Role of atrial substrate and spatiotemporal organization in atrial fibrillation., in Heart Rhythm, vol. 6, 8 Suppl, agosto 2009, pp. S1-7, DOI:10.1016/j.hrthm.2009.02.010, PMID 19631905.
P. Kirchhof et al., Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'., in Eur Heart J, vol. 30, n. 24, dicembre 2009, pp. 2969-77c, DOI:10.1093/eurheartj/ehp235, PMID 19535417.
DM. Hodgson-Zingman et al., Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation., in N Engl J Med, vol. 359, n. 2, luglio 2008, pp. 158-65, DOI:10.1056/NEJMoa0706300, PMID 18614783.
DF. Gudbjartsson et al., A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke., in Nat Genet, vol. 41, n. 8, agosto 2009, pp. 876-8, DOI:10.1038/ng.417, PMID 19597491.
S. Neef, LS. Maier, Novel aspects of excitation-contraction coupling in heart failure., in Basic Res Cardiol, vol. 108, n. 4, luglio 2013, p. 360, DOI:10.1007/s00395-013-0360-2, PMID 23740218.
SM. Chaldoupi et al., The role of connexin40 in atrial fibrillation., in Cardiovasc Res, vol. 84, n. 1, ottobre 2009, pp. 15-23, DOI:10.1093/cvr/cvp203, PMID 19535379.
B. Burstein, S. Nattel, Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation., in J Am Coll Cardiol, vol. 51, n. 8, febbraio 2008, pp. 802-9, DOI:10.1016/j.jacc.2007.09.064, PMID 18294563.
D. Rahmutula et al., Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1., in Cardiovasc Res, vol. 99, n. 4, settembre 2013, pp. 769-79, DOI:10.1093/cvr/cvt074, PMID 23612580.
SN. Reilly et al., Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins., in Circulation, vol. 124, n. 10, settembre 2011, pp. 1107-17, DOI:10.1161/CIRCULATIONAHA.111.029223, PMID 21844076.
JY. Youn et al., Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase., in J Mol Cell Cardiol, vol. 62, settembre 2013, pp. 72-9, DOI:10.1016/j.yjmcc.2013.04.019, PMID 23643589.
J. Kornej et al., The emerging role of biomarkers in atrial fibrillation., in Can J Cardiol, vol. 29, n. 10, ottobre 2013, pp. 1181-93, DOI:10.1016/j.cjca.2013.04.016, PMID 23962731.
(EN) [Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)], Guidelines for the management of atrial fibrillation, in European Heart Journal, n. 31, 2010, pp. 2369-2429, DOI:10.1093/eurheartj/ehq278.
AR. Kansal, M. Sharma; C. Bradley-Kennedy; A. Clemens; BU. Monz; S. Peng; N. Roskell; SV. Sorensen, Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness., in Thromb Haemost, vol. 108, n. 4, settembre 2012, pp. 672-82, DOI:10.1160/TH12-06-0388, PMID 22898892.
S. Deitelzweig, A. Amin; Y. Jing; D. Makenbaeva; D. Wiederkehr; J. Lin; J. Graham, Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials., in J Med Econ, vol. 15, n. 4, 2012, pp. 776-85, DOI:10.3111/13696998.2012.680555, PMID 22449118.
J. Steffel, E. Braunwald, Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism., in Eur Heart J, vol. 32, n. 16, agosto 2011, pp. 1968-76, 1976a, DOI:10.1093/eurheartj/ehr052, PMID 21421599.

onlinejacc.org

(EN) January CT et al., 2014 AHA/ACC/HR, guideline for the management of patients with atrial ﬁbrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society, in J Am Coll Cardiol, n. 64, 2014, pp. 2246-2280. URL consultato il 27 ottobre 2018.

oxfordjournals.org

eurheartj.oxfordjournals.org

(EN) Heeringa, et al., Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study ^{[collegamento interrotto]} (abstract), in European Heart Journal, n. 27, marzo 2006, pp. 949-953. URL consultato il 9 gennaio 2009.

web.archive.org

Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA), su cabanatrial.org. URL consultato il 17 agosto 2015 (archiviato dall'url originale il 5 settembre 2015).
BRINAVESS (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation, su merck.com, Merck & Co., Inc., 1º settembre 2010. URL consultato il 28 settembre 2010 (archiviato dall'url originale il 28 settembre 2010).